个人中心 - 老虎社区

九月168

IP属地：广东

帖子 · 6帖子 · 6
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- 九月168九月168
  ·01-23
  $荃信生物-B(02509)$ 现在22港币，买进去就等于踩中三重机会：业绩要拐点、管线能兑现、估值还得修复！短期有两大利好，QX002N马上提交上市申请，赛乐信销量也在持续涨；中期好几款三期产品会陆续上市；长期还有双抗要出海，直接冲全球市场，中金给的目标价33块，完全是把这些潜在价值算透了的合理价，后续上涨劲头肯定足。
  295 评论
  1
  分享
  举报
- 九月168九月168
  ·01-16
  $荃信生物-B(02509)$ 有新进展，靶向IL-23p19和TL1A的双抗QX030N/CLD-423，已经给首批健康志愿者用药，正式进入I期临床啦，这药瞄准炎症性肠病，双靶点协同起效，潜力不小呢。
  389 评论
  1
  分享
  举报
- 九月168九月168
  ·01-09
  $荃信生物-B(02509)$ JKN2401注射液，已经正式进入III期临床试验。这个药主要是针对中重度慢阻肺患者的，那种平时总咳嗽、咳痰，稍微动一动就喘不上气的毛病。III期临床试验是新药上市前很关键的一步，会找更多患者测试，进一步确认药效和安全性，相当于给药物的效果和安全性做最终把关，这可是给受慢阻肺困扰的朋友们带来了新希望呀。
  557 评论
  1
  分享
  举报
- 九月168九月168
  ·2025-08-19
  666啊，能加吗，会不会冲进包围圈
  1,617 评论
  1
  分享
  举报
- 九月168九月168
  ·2025-08-19
  估计暗盘怎么也能翻一倍
  1,582 评论
  1
  分享
  举报
- 九月168九月168
  ·2025-08-19
  多涨一点，[笑哭] [笑哭] [笑哭]
  1,437 评论
  1
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4215846347868680","uuid":"4215846347868680","gmtCreate":1752743160296,"gmtModify":1752743222973,"name":"九月168","pinyin":"jy168jiuyue168","introduction":"","introductionEn":null,"signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":0,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[],"userBadgeCount":0,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"广东","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":524999463092496,"gmtCreate":1769150356031,"gmtModify":1769150358468,"author":{"id":"4215846347868680","authorId":"4215846347868680","name":"九月168","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4215846347868680","idStr":"4215846347868680"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02509\">$荃信生物-B(02509)$ </a> 现在22港币，买进去就等于踩中三重机会：业绩要拐点、管线能兑现、估值还得修复！短期有两大利好，QX002N马上提交上市申请，赛乐信销量也在持续涨；中期好几款三期产品会陆续上市；长期还有双抗要出海，直接冲全球市场，中金给的目标价33块，完全是把这些潜在价值算透了的合理价，后续上涨劲头肯定足。","listText":"<a href=\"https://laohu8.com/S/02509\">$荃信生物-B(02509)$ </a> 现在22港币，买进去就等于踩中三重机会：业绩要拐点、管线能兑现、估值还得修复！短期有两大利好，QX002N马上提交上市申请，赛乐信销量也在持续涨；中期好几款三期产品会陆续上市；长期还有双抗要出海，直接冲全球市场，中金给的目标价33块，完全是把这些潜在价值算透了的合理价，后续上涨劲头肯定足。","text":"$荃信生物-B(02509)$ 现在22港币，买进去就等于踩中三重机会：业绩要拐点、管线能兑现、估值还得修复！短期有两大利好，QX002N马上提交上市申请，赛乐信销量也在持续涨；中期好几款三期产品会陆续上市；长期还有双抗要出海，直接冲全球市场，中金给的目标价33块，完全是把这些潜在价值算透了的合理价，后续上涨劲头肯定足。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/524999463092496","isVote":1,"tweetType":1,"viewCount":295,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":522268611646640,"gmtCreate":1768542952961,"gmtModify":1768542956182,"author":{"id":"4215846347868680","authorId":"4215846347868680","name":"九月168","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4215846347868680","idStr":"4215846347868680"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02509\">$荃信生物-B(02509)$ </a> 有新进展，靶向IL-23p19和TL1A的双抗QX030N/CLD-423，已经给首批健康志愿者用药，正式进入I期临床啦， 这药瞄准炎症性肠病，双靶点协同起效，潜力不小呢。","listText":"<a href=\"https://laohu8.com/S/02509\">$荃信生物-B(02509)$ </a> 有新进展，靶向IL-23p19和TL1A的双抗QX030N/CLD-423，已经给首批健康志愿者用药，正式进入I期临床啦， 这药瞄准炎症性肠病，双靶点协同起效，潜力不小呢。","text":"$荃信生物-B(02509)$ 有新进展，靶向IL-23p19和TL1A的双抗QX030N/CLD-423，已经给首批健康志愿者用药，正式进入I期临床啦， 这药瞄准炎症性肠病，双靶点协同起效，潜力不小呢。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/522268611646640","isVote":1,"tweetType":1,"viewCount":389,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":520073446617128,"gmtCreate":1767945366699,"gmtModify":1767945369672,"author":{"id":"4215846347868680","authorId":"4215846347868680","name":"九月168","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4215846347868680","idStr":"4215846347868680"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02509\">$荃信生物-B(02509)$ </a> JKN2401注射液，已经正式进入III期临床试验。 这个药主要是针对中重度慢阻肺患者的，那种平时总咳嗽、咳痰，稍微动一动就喘不上气的毛病。III期临床试验是新药上市前很关键的一步，会找更多患者测试，进一步确认药效和安全性，相当于给药物的效果和安全性做最终把关，这可是给受慢阻肺困扰的朋友们带来了新希望呀。","listText":"<a href=\"https://laohu8.com/S/02509\">$荃信生物-B(02509)$ </a> JKN2401注射液，已经正式进入III期临床试验。 这个药主要是针对中重度慢阻肺患者的，那种平时总咳嗽、咳痰，稍微动一动就喘不上气的毛病。III期临床试验是新药上市前很关键的一步，会找更多患者测试，进一步确认药效和安全性，相当于给药物的效果和安全性做最终把关，这可是给受慢阻肺困扰的朋友们带来了新希望呀。","text":"$荃信生物-B(02509)$ JKN2401注射液，已经正式进入III期临床试验。 这个药主要是针对中重度慢阻肺患者的，那种平时总咳嗽、咳痰，稍微动一动就喘不上气的毛病。III期临床试验是新药上市前很关键的一步，会找更多患者测试，进一步确认药效和安全性，相当于给药物的效果和安全性做最终把关，这可是给受慢阻肺困扰的朋友们带来了新希望呀。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/520073446617128","isVote":1,"tweetType":1,"viewCount":557,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":469219663003960,"gmtCreate":1755586403699,"gmtModify":1755586405548,"author":{"id":"4215846347868680","authorId":"4215846347868680","name":"九月168","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4215846347868680","idStr":"4215846347868680"},"themes":[],"htmlText":"666啊，能加吗，会不会冲进包围圈","listText":"666啊，能加吗，会不会冲进包围圈","text":"666啊，能加吗，会不会冲进包围圈","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/469219663003960","isVote":1,"tweetType":1,"viewCount":1617,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":469219255787792,"gmtCreate":1755586303490,"gmtModify":1755586339619,"author":{"id":"4215846347868680","authorId":"4215846347868680","name":"九月168","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4215846347868680","idStr":"4215846347868680"},"themes":[],"htmlText":"估计暗盘怎么也能翻一倍","listText":"估计暗盘怎么也能翻一倍","text":"估计暗盘怎么也能翻一倍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/469219255787792","isVote":1,"tweetType":1,"viewCount":1582,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":469216815137312,"gmtCreate":1755586191809,"gmtModify":1755586319452,"author":{"id":"4215846347868680","authorId":"4215846347868680","name":"九月168","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4215846347868680","idStr":"4215846347868680"},"themes":[],"htmlText":"多涨一点，[笑哭]&nbsp;&nbsp;[笑哭]&nbsp;&nbsp;[笑哭]&nbsp;&nbsp;","listText":"多涨一点，[笑哭]&nbsp;&nbsp;[笑哭]&nbsp;&nbsp;[笑哭]&nbsp;&nbsp;","text":"多涨一点，[笑哭] [笑哭] [笑哭]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/469216815137312","isVote":1,"tweetType":1,"viewCount":1437,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}